Tyra Biosciences, Inc. (TYRA) Stock Price & Analysis
Tyra Biosciences, Inc. (TYRA) closed at USD 20.87 on Thursday, October 22, 2026, up 1.31% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.6; the Oct 22, 2026 session ranged USD 20.22–21.28 on volume of 826,145 shares. Market capitalization is $1.43B, with a 52-week range of USD 13.35–40.65 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TYRA.md
Key facts (TYRA)
- Analysts: Buy (mean 1.93 on a 1–5 scale) (15 analysts), mean target USD 47.45 (range 29–59).
- Total return with dividends: 1Y +47.8% vs S&P 500 +14.9%; 5Y -9.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.67, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TYRA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$26.3M | -$58.9M | -$79.9M | -$104M | -$133M | -$160M |
| Net income | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$120M | -$149M |
| EPS (diluted) | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 | — |
| Free cash flow | -$24.4M | -$50.8M | -$50.9M | -$70.4M | -$95.3M | -$110M |
| Cash + short-term investments | $302M | $251M | $58.0M | $92.0M | $77.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TYRA)
P/B 4.1x · FCF yield -7.66% · Earnings yield -10.35%
Analysts (TYRA)
Consensus Buy (mean 1.93 on a 1–5 scale), 15 analysts; mean target USD 47.45 (low 29, high 59).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | Oppenheimer | Target lowered | Outperform | $50 → $40 |
| 2026-09-22 | HC Wainwright & Co. | Target lowered | Buy | $30 → $29 |
| 2026-09-10 | Wedbush | Reiterated | Outperform | $53 |
| 2026-09-10 | HC Wainwright & Co. | Target lowered | Buy | $45 → $30 |
| 2026-09-04 | HC Wainwright & Co. | Reiterated | Buy | $45 |
Total return (dividends reinvested) (TYRA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +47.8% | -9.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +48.0% | -1.9% |
| Volatility (annualized) | 67.3% | 81.8% |
| Max drawdown | -53.2% (Apr 2026→Oct 2026) | -81.5% (Nov 2021→Jun 2022) |
TYRA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.67 | $-0.65 | +2.7% | $0 | 14 |
| Next quarter (ends Dec 2026) | $-0.67 | $-0.67 | -0.4% | $0 | 14 |
| Current fiscal year (ends Dec 2026) | $-2.64 | $-2.58 | +2.2% | $0 | 14 |
| Next fiscal year (ends Dec 2027) | $-2.77 | $-2.82 | -1.7% | $0 | 14 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 20.87 |
|---|---|
| Change | ▲ 1.31% (up) |
| Previous Close | USD 20.6 |
| Open | USD 20.58 |
| Day Range | USD 20.22 – 21.28 |
| 52-Week Range | USD 13.35 – 40.65 |
| Volume | 826,145 shares |
| Market Cap | $1.43B |
| Exchange | NMS |
Technical Analysis (TYRA)
Nexqual's technical model rates TYRA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.75 (neutral) |
| vs SMA50 | Below (USD 23.24) |
| MACD | -1.04 (negative) |
Analyst Ratings (TYRA)
Wall Street analysts rate TYRA "Buy" based on 15 analysts, with a mean price target of USD 47.45 (range USD 29–59), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 47.45 |
| High Target | USD 59 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (TYRA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.69 vs est -0.64 ▼ miss |
| 2026-03-31 | USD -0.64 vs est -0.59 ▼ miss |
| 2025-12-31 | USD -0.57 vs est -0.53 ▼ miss |
| 2025-09-30 | USD -0.5 vs est -0.51 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (TYRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -45.31% |
| Debt / Equity | 0.02 |
| Current Ratio | 14.91 |
| Total Cash | $353.94M |
| Total Debt | $5.58M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (TYRA)
Nexqual rates Tyra Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $354M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$95M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -45%, ROA -28.5% |
Ownership (TYRA)
| Insider Ownership | +2.43% |
|---|---|
| Institutional Ownership | +108.29% |
| Shares Outstanding | 68.76M |
| Float | 34.65M |
| Short % of Float | +22.71% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (TYRA)
Tyra Biosciences, Inc. is led by Todd Harris, Co-Founder, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| Co-Founder, CEO, President & Director | Todd Harris |
|---|---|
| Chief Operating Officer | Bhavesh Ashar |
| Chief Financial Officer | Alan Fuhrman |
| Chief Technology Officer | Robert L. Hudkins |
| Chief Scientific Officer | Ronald V. Swanson |
Major Backers & Investors (TYRA)
Notable institutional backers of Tyra Biosciences, Inc. include RA Capital Management, L.P., FMR, LLC, Fidelity, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 20.44% |
| FMR, LLC | 14.95% |
| Fidelity | 7.37% |
| Jupiter Topco LLC | 7.29% |
| Alta Partners Management Company, L.P. | 6.41% |
| Nextech Invest, Ltd. | 5.95% |
| TCG Crossover Management, LLC | 5.44% |
| Price (T.Rowe) Associates Inc | 4.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.08% |
| State Street | 3.59% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt